Newsletter of MEDICA | View in browser | Deutsch | Print

Vaccinations made easy

Dear Sir or Madam,

at LTS Lohmann Therapie-Systeme AG, microneedle array patches (MAPs) are revolutionizing vaccination technology. In our interview, Dr. Frank Theobald, head of the MAP program, emphasizes the advantages: painless application, reduced cold chain requirements, and high efficiency. This innovation enables easier vaccinations worldwide, especially in resource-poor countries, and promises broader medical applications.

Enjoy reading!

Tim Plato
Editorial team MEDICA-tradefair.com

	Interview: Microneedle array patches
	Newsletter Service

Image: Banner with the text: MEDICA Magazine – 365 days a year; Copyright: Messe Düsseldorf

Microneedle array patches: vaccinations made easy

Interview – LAB & DIAGNOSTICS

Image: A woman in a blue lab coat sticks a patch on the arm of a young girl, both wearing a mask

Dissolvable microneedle array patches (MAPs) consist of tiny, rapidly dissolving needles that can efficiently deliver vaccines into the skin. Their stability over time and easy application gives them great potential to not only simplify the vaccination process during a pandemic, but also in increase vaccination rates in low- and middle-income countries.

Click here for the interview

	Microneedle array patches: vaccinations made easy
	Read all content from the Sphere of LAB & DIAGNOSTICS in the MEDICA Magazine here

To top

Monitoring Atrial Fibrillation with smart bracelet

News

DIGITAL HEALTH

Atrial fibrillation, the most prevalent heart rhythm disorder impacting 33 million people worldwide, can have serious consequences if left untreated. To address this pressing issue, researchers have unveiled a technology aimed at identifying and managing individual factors contributing to atrial fibrillation.

To top

Contact lenses for early glaucoma detection

News

MED TECH & DEVICES

Glaucoma affects approximately 70 million people worldwide and poses a significant threat to vision, often leading to irreversible vision loss if left untreated. Nearly half of those afflicted with this condition remain unaware of its presence. Typically progressing gradually, glaucoma often escapes early detection, making it crucial to develop new tools for its timely diagnosis and treatment.

To top

Advancing reproductive medicine: Funding opportunities

News

MED TECH & DEVICES

Jena University Hospital and Friedrich Schiller University Jena proudly announce the establishment of the Jena Center for Early Pregnancy and Reproductive Health (CEPRE), a dynamic interdisciplinary initiative aimed at fostering innovative research in women's reproductive health and early pregnancy.

To top

Nasal antibody spray demonstrates potential for COVID-19 prevention

News

LAB & DIAGNOSTICS

Researchers at the Karolinska Institutet in Sweden have achieved a significant breakthrough in COVID-19 prevention with the development of a nasal antibody spray. This approach offers new possibilities for enhanced protection against SARS-CoV-2 and its various variants, providing hope for high-risk individuals.

To top

Newsletter Service

You like our newsletter? Then please recommend us: Forward this newsletter or the link www.MEDICA.de/news_login_2 to your friends and colleagues.

If you have difficulties with your order, please write an e-mail to redaktion@medica.de.

To top

Legal disclaimer

Messe Düsseldorf GmbH
Messeplatz, Stockumer Kirchstr. 61
40474 Düsseldorf, Germany

Phone: +49 211 4560-01
Fax: +49 211 4560-668
www.messe-duesseldorf.de
info@messe-duesseldorf.de

County Court Düsseldorf HRB 63

Board of Managing Directors: Wolfram N. Diener (Chairman), Marius Berlemann, Bernhard J. Stempfle

Chairman of Supervisory Board: Mayor Dr. Stephan Keller

Messe Düsseldorf GmbH processes personal data relating to you. You can find more information - also on your rights - in the privacy policy of Messe Düsseldorf GmbH available at www.messe-duesseldorf.de/privacy. In principle, i.e. subject to legal restrictions, you may at any time object to the processing of your personal data either on the aforementioned website, via e-mail to privacy@messe-duesseldorf.de or via postal mail to Messe Düsseldorf GmbH, G2-RV, PF 101006, 40001 Düsseldorf, Germany.